Cisplatin-Dependent Nephrotoxicity in Patients with Lung Cancer

Basit Öğe Kaydı
dc.authoridOzdemir, Levent/0000-0002-3478-5454;
dc.authorwosidOzdemir, Levent/AEV-9509-2022
dc.authorwosid, Osman/AGR-7980-2022
dc.authorwosid, osman/HRD-6024-2023
dc.contributor.authorOzdemir, Burcu
dc.contributor.authorOzdemir, Levent
dc.contributor.authorHatipoglu, Osman
dc.contributor.authorTabakoglu, Erhan
dc.contributor.authorAltiay, Gundeniz
dc.date.accessioned2024-06-12T11:07:53Z
dc.date.available2024-06-12T11:07:53Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description.abstractOBJECTIVE The aim of the present study was to investigate nephrotoxicity development ratios and clinical results of nephrotoxicity in patients diagnosed with lung cancer who received cisplatin in chemotherapy protocol. METHODS A total of 170 lung cancer patients were enrolled in the present prospective study. Renal functions were recorded for each patient before and after chemotherapy. Nephrotoxicity was defined as doubling in plasma creatinine concentration. Modification in treatment due to nephrotoxicity (reduction in cisplatin dosage, cisplatin interruption, or discontinuation of chemotherapy) was recorded during chemotherapy courses. RESULTS Decreasement of creatinine clearance levels was observed following each course of chemotherapy, but was especially noteworthy following the 1st and 5th courses (p=0.002; p=0.007, respectively). Nephrotoxicity was observed in 19 of the 170 patients (11%), in 10 of whom (53%) cisplatin dosage was reduced, and in 8 of whom (42%), cisplatin treatment was interrupted. Chemotherapy was discontinued in 1 patient (5%). CONCLUSION Particularly following the fourth course, chemotherapy must be carefully administered due to risk of nephrotoxicity.en_US
dc.identifier.endpage17en_US
dc.identifier.issn1300-7467
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-84964523388en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage15en_US
dc.identifier.trdizinid240990en_US
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/240990
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22217
dc.identifier.volume31en_US
dc.identifier.wosWOS:000379361500004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofTurk Onkoloji Dergisi-Turkish Journal Of Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLung Canceren_US
dc.subjectCisplatinen_US
dc.subjectNephrotoxicityen_US
dc.titleCisplatin-Dependent Nephrotoxicity in Patients with Lung Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu